Tier 3 — preclinical

A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD + metabolism

Maric T, Bazhin A, Khodakivskyi P, Mikhaylov G, Solodnikova E, Yevtodiyenko A, Giordano Attianese GMP, Coukos G, Irving M, Joffraud M, Cantó C, Goun E
Biosensors & bioelectronics 2023 220; 114826

Bibliography

PubMed
PMID 36371959
DOI
10.1016/j.bios.2022.114826
Funding
Funding details are not specified in the accessible publication information.
Competing interests
The authors reported no competing interests.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelCultured cells, human cell samples and tumor-bearing mice
SampleCell assays and a triple-negative breast-cancer mouse model
InterventionNR supplementation and a bioluminescent NR-uptake probe
DurationModel-specific uptake and tumor experiments
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

The imaging study linked NR uptake with tumor metabolism and reported more cancer and brain metastases in a specific mouse model.

Key findings

The imaging study linked NR uptake with tumor metabolism and reported more cancer and brain metastases in a specific mouse model.

What this study can and cannot tell us

Preclinical cancer-model evidence does not establish that ordinary oral NR use causes cancer in humans or quantify human cancer risk.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology